Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

NCT02143726 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Refractory Hurthle Cell Thyroid Cancer

Interventions

DRUG: sorafenib
DRUG: everolimus

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]
[object Object]